WellSync’s BoomRx tops $70 million run rate
The prescription-management platform now serves over 4,500 clinics, processes 40,000+ orders monthly, and surpasses a $70 million annual rate within a year of launch.
The prescription-management platform now serves over 4,500 clinics, processes 40,000+ orders monthly, and surpasses a $70 million annual rate within a year of launch.
IPC members can now deliver seamless prescription access, mobile refills, and more through Nimble.
These appointments reflect iA’s ongoing investment in strengthening its leadership team and aligning capabilities across finance, technology, and product development.
National patient survey finds cost confusion, prior authorization delays can derail care, but technology can unlock price transparency, improv access.
"By forcing the closure of more than 160 PBM-affiliated retail, specialty, and mail-order pharmacies across the state, lawmakers are creating harmful new barriers for patients."
The test will be whether the shifts bring savings and less complexity for patients and pharmacies.
A new Pacific Research Institute report warns that unauthorized compounded GLP-1 drugs may pose patient safety risks and hinder future pharmaceutical innovation.
Building on decade-long commitment to outbreak relief.
Benefits from high-fiber foods include lower cholesterol, more balanced blood sugar levels and improved energy levels.
Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups.
“Being prescribed Zepbound helped make a difference for me in my OSA treatment journey; I even lost some weight,” O’Neal said.
NACDS is advising chain pharmacy members on the upcoming launch of the CMS Medicare GLP-1 Bridge Program, a temporary demonstration that will provide eligible Medicare beneficiaries with access to certain medications beginning July 1.
The court unanimously ruled that Hikma's generic version of Amarin’s cardiovascular drug Vascepa (icosapent ethyl) does not infringe on the branded drug maker's patents.
The panel shared trends and tools to optimize biosimilar adoption to lower plan costs while supporting optimal health outcomes for members.